Dr. Atul Verma and Dr. C. Michael Gibson Discuss: OCEAN – The Need for Ongoing Oral Anticoagulation in Patients with Clinical Stroke Risk Factors After Successful Catheter Ablation of Atrial Fibrillation: The OCEAN Randomized Trial November 8, 2025 Disclosures: TBD
Dr. Jeffrey I Weitz and Dr. C. Michael Gibson Discuss: ROXI~ Two Mechanistically Distinct Factor XI Antibodies, REGN9933 and REGN7508, for the Prevention of Venous Thromboembolism After Knee Arthroplasty: the ROXI-VTE-I and ROXI-VTE-II trials November 8, 2025 Disclosures: TBD
Dr. Paul Burton and Dr. C. Michael Gibson Discuss: Effect of Evolocumab in Patients at High Cardiovascular Risk without Prior Myocardial Infarction or Stroke: Primary Results of the VESALIUS-CV trial November 8, 2025 Disclosures: TBD
Dr. Ankeet Bhatt and Dr. C. Michael Gibson Discuss: Electronic Nudges to Increase Influenza Vaccination Among Patients With History of Myocardial Infarction: Insights From 3 Randomized Clinical Trials Enrolling >2 Million Patients (NUDGE-FLU) November 17, 2024 Disclosures: TBD
Dr. Paul Ridker and Dr. C. Michael Gibson Discuss: CLEAR OUTCOMES subanalysis on predicting CV events November 13, 2023 Disclosures: TBD
Dr. Richard Wright and Dr. C. Michael Gibson Discuss: The Genetic / Mendalian randomization (natures randomized trial) data that supports the efficacy of Acoramadis in amyloidosis and the potential for amyloid regression with therapy November 13, 2023 Disclosures: TBD
Dr. Charalambos Antoniades and Dr. C. Michael Gibson Discuss: Novel AI Technology to Improve Risk Stratification of Patients Without Obstructive Coronary Artery Disease Undergoing CCTA: The Oxford Risk Factors and Non-Invasive Imaging (ORFAN) Study November 13, 2023 Disclosures: TBD
Dr. Alexander Fanaroff Presents: A Cluster Randomized Trial of Automated Referral to Centralized Pharmacy Services for Evidence-Based Statin Initiation in High-Risk Patients November 13, 2023 Disclosures: TBD
Dr. Daniel Judge and Dr. C. Michael Gibson: Acoramidis from bench to bedside November 12, 2023 Disclosures: TBD
Dr. Steven Nissen and Dr. C. Michael Gibson Discuss: Efficacy and Safety of Lepodisiran: An Extended Duration Short-Interfering RNA Targeting Lipoprotein (a) November 12, 2023 Disclosures: TBD
